Evidence map›Paper›PMID 40492736›Full record

ArticleJournal of virology2025

Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques.

Gabriella Worwa, Carl W Davis, Sarah E Klim, Jacquelyn Turcinovic, Krystle N Agans, Viktoriya Borisevich, Joan B Geisbert, Robert W Cross, Anya Crane, Michael R Holbrook and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gabriella WorwaIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, USA.ORCID 0000-0001-7485-2204
Carl W DavisEmory Vaccine Center and Department of Microbiology and Immunology, Emory University , Atlanta, Georgia, USA.
Sarah E KlimIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, USA.
Jacquelyn TurcinovicGalveston National Laboratory, Galveston, Texas, USA.ORCID 0000-0002-7669-223X
Krystle N AgansGalveston National Laboratory, Galveston, Texas, USA.
Viktoriya BorisevichGalveston National Laboratory, Galveston, Texas, USA.
Joan B GeisbertGalveston National Laboratory, Galveston, Texas, USA.
Robert W CrossGalveston National Laboratory, Galveston, Texas, USA.
Anya CraneIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, USA.
Michael R HolbrookIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, USA.
Mariano Sanchez-LockhartUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA.
Jeffrey R KugelmanUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA.
Juan A Patino GalindoIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Thomas W GeisbertGalveston National Laboratory, Galveston, Texas, USA.ORCID 0000-0003-0858-1877
Rafi AhmedEmory Vaccine Center and Department of Microbiology and Immunology, Emory University , Atlanta, Georgia, USA.ORCID 0000-0002-9591-2621
Jens H KuhnIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, Maryland, USA.ORCID 0000-0002-7800-6045
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Gustavo PalaciosIcahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-5062-1938
Ian CrozierClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0003-2485-4011

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Thomas Gary Ksiazek · 2011 to 2026
$208.8M
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
NCI NIH HHS 75N91019D00024NIAID NIH HHS U19 AI142790NIAID NIH HHS UC7 AI094660NIH HHS HHSN272200700016INIH HHS HHSN272201800013C
6 · The paper itself

Abstract

A cocktail of human monoclonal antibodies 1C3 and 1C11 previously protected macaques from a lethal exposure to either Ebola virus (EBOV) or Sudan virus (SUDV). 1C3 is of particular interest because its paratope strongly binds with unique stoichiometry to the glycoprotein head of several orthoebolaviruses, resulting in neutralization of EBOV and SUDV. Therefore, we evaluated the protective activity of 1C3 as a standalone therapeutic in macaques exposed to either EBOV or SUDV. Two doses of 1C3 monotherapy, administered 4 and 7 days post-exposure, did not protect SUDV-exposed macaques and partially protected EBOV-exposed macaques. Notably, in a macaque that succumbed to EBOV infection, we identified two mutually exclusive escape mutations that emerged immediately after the first dose and resulted in two amino acid changes at the 1C3 binding site. We also detected a subconsensus treatment-emergent mutation likely affecting the 1C3 binding site in all three deceased SUDV-exposed macaques. Our findings highlight combination treatment with 1C11 as critical for protection, particularly against SUDV, and IMPORTANCE: A cocktail of human monoclonal antibodies 1C3 and 1C11 previously protected macaques exposed to a lethal dose of either Ebola virus (EBOV) or Sudan virus (SUDV). Since the unique binding characteristics of 1C3 are of particular interest, we evaluated its protective activity as monotherapy in macaques exposed to either EBOV or SUDV. Two doses of 1C3 alone did not protect SUDV-exposed macaques and only partially protected EBOV-exposed macaques. Importantly, failure to protect was associated with the rapid emergence of previously

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEbolavirusHemorrhagic Fever, EbolaAnimalsDisease Models, AnimalHumansMacacaMutationAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, Viral1C111C3Ebola virusEBOVescape mutationglycoproteinmonoclonal antibodyorthoebolaviruspartial protectionSudan virusSUDV

Identifiers

PMID40492736
PMCPMC12282081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.